Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Total Non-current Liabilities
All obligations due after more than one year.
Actuate Therapeutics IncNASDAQ: ACTU
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 2.8% from a year ago
Total non-current liabilities stood at $404.99K at the end of Q1 FY2026, down 2.8% from a year earlier and down 0.0% from the prior quarter. Over 3 fiscal years it compounded at -32.3% a year.
Context
- Total non-current liabilities amounted to 4.5% of total assets at the end of Q1 FY2026, down 4.8 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -2.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 404.99K USD
- Year-over-year change
- -1.6%
- 3-year CAGR
- -32.3%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 404.99K | -1.6% |
| FY2024 | 2024-12-31 | 411.76K | -99.6% |
| FY2023 | 2023-12-31 | 95.7M | +7229.2% |
| FY2022 | 2022-12-31 | 1.31M | — |
Total Non-current Liabilities vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -2.8% is the 4th highest of 9, against a peer median of -7.2%.
- Total non-current liabilities amounts to 4.5% of total assets for ACTU, versus a peer median of 39.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $641.09M USD | +2317.8% | +156.8% | 126.5% | |
| Mar 2026 | $188.57M USD | -7.5% | -26.1% | 78.6% | |
| Mar 2026 | $71.78M USD | -12.9% | -33.4% | 61.0% | |
| Mar 2026 | $68.01M USD | -6.9% | -4.0% | 18.3% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $16.9M USD | +115.9% | +32.8% | 74.5% |
| Mar 2026 | $13.35M USD | -11.9% | -10.0% | 8.5% | |
| Mar 2026 | CHF 10.38M CHF | +163.4% | +3.0% | 11.9% | |
| Mar 2026 | $598K USD | -95.9% | -66.4% | 1.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $404.99K USD | -2.8% | -32.3% | 4.5% |
| Peer median (excluding ACTU) | — | -7.2% | -7.0% | 39.7% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.